https://www.selleckchem.com/pr....oducts/azd5153-6-hyd
by most caregivers and noncaregivers due to its ease of use. Additional studies of intranasal glucagon in younger patients (1- less then 3 years of age), pregnant women, and in comparison with SC glucagon are needed to further clarify bioavailability, efficacy, and tolerability. Dual antiplatelet therapy (DAPT) with aspirin and a P2Y inhibitor is currently recommended to prevent further ischemic events after percutaneous coronary intervention and acute coronary syndrome (ACS). Guidelines currently recommend a
Like
Comment
Share
